 CAMBRIDGE, Mass.--BUSINESS WIRE--Syros Pharmaceuticals NASDAQ:SYRS, a leader in the development of medicines that control the expression of genes, today announced that it has entered into a clinical supply agreement with Roche. Under the agreement, Syros will supply SY-5609, its highly selective and potent oral inhibitor of cyclin-dependent kinase 7 CDK7, for a combination dosing cohort in Roches ongoing Phase 11b INTRINSIC trial, which is evaluating multiple targeted therapies or immun 